Revenue Breakdown
Composition ()
No data
Revenue Streams
Avadel Pharmaceuticals PLC (AVDL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Vazculep, accounting for 48.7% of total sales, equivalent to $4.92M. Other significant revenue streams include Akovaz and Bloxiverz. Understanding this composition is critical for investors evaluating how AVDL navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Avadel Pharmaceuticals PLC maintains a gross margin of 93.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9.76%, while the net margin is 0.03%. These profitability ratios, combined with a Return on Equity (ROE) of -0.32%, provide a clear picture of how effectively AVDL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AVDL competes directly with industry leaders such as HRMY and MAZE. With a market capitalization of $2.11B, it holds a leading position in the sector. When comparing efficiency, AVDL's gross margin of 93.05% stands against HRMY's 75.09% and MAZE's N/A. Such benchmarking helps identify whether Avadel Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.
